We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
Cap. Flow
-$2.79B
Cap. Flow %
-20.16%
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194

Top Buys

Rank Stock Value
1
LRCX icon
Lam Research
LRCX
+$66.4M
2
VLO icon
Valero Energy
VLO
+$28.9M
3
SLB icon
SLB Ltd
SLB
+$24.8M
4
BNY
Bank of New York Mellon
BNY
+$22.6M
5
PEP icon
PepsiCo
PEP
+$20.4M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$182M
2
AAPL icon
Apple
AAPL
+$148M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$90.9M
4
AMGN icon
Amgen
AMGN
+$72.1M
5
TSLA icon
Tesla
TSLA
+$66.1M

Sector Composition

Rank Sector Weight
1 Healthcare 31.26%
2 Technology 28.78%
3 Financials 8.15%
4 Consumer Discretionary 7.54%
5 Industrials 7.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WRK
851
DELISTED
WestRock Company
WRK
– –
-14,334
Closed -$402K
AEL
852
DELISTED
American Equity Investment Life Holding Company
AEL
– –
-52,895
Closed -$1.78M
NGM
853
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-152,187
Closed -$572K
MDRX
854
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-33,580
Closed -$403K
NVTA
855
DELISTED
Invitae Corporation
NVTA
– –
-306,051
Closed -$380K
SYNH
856
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-13,373
Closed -$438K
RETA
857
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-5,377
Closed -$450K
DICE
858
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-210,000
Closed -$5.54M
VRAY
859
DELISTED
ViewRay, Inc.
VRAY
– –
-1,812,970
Closed -$5.77M
RXDX
860
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-90,000
Closed -$8.89M
MNTV
861
DELISTED
Momentive Global Inc. Common Stock
MNTV
– –
-421,076
Closed -$3.61M
MAXR
862
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
– –
-22,482
Closed -$1.06M
FRC
863
DELISTED
First Republic Bank
FRC
– –
-13,802
Closed -$178K
OSH
864
DELISTED
Oak Street Health, Inc.
OSH
– –
-171,495
Closed -$6.11M
PRVB
865
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-18,922
Closed -$420K
SJR
866
DELISTED
Shaw Communications Inc.
SJR
– –
-313,241
Closed -$8.62M
CTIC
867
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-240,000
Closed -$928K
DISH
868
DELISTED
DISH Network Corp.
DISH
– –
-57,700
Closed -$496K
31 32 33 34
35

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2023 Portfolio in Review

As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.

Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.

  • Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
  • Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
  • Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
  • Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
  • Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
  • Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
  • Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.